Litigation
Sun Pharmaceutical Industries Ltd. et al. v. Lupin Ltd. et al.
settled and dismissed with prejudice3:18-cv-02213
Auto-generating section 1 of 4: Case overview & background…
Each section takes ~30-60s with web-search grounding. Keep this tab open — sections will fill in below as they complete.
- Filed
- 2018-02-15
Patents at issue (1)
Plaintiffs (3)
Defendants (2)
Summary
Hatch-Waxman ANDA infringement action by Sun against Lupin concerning Lupin's ANDA No. 211239 for bromfenac ophthalmic solution 0.075%. The court found the ’999 patent not literally infringed, obvious, and indefinite, but the case was settled and dismissed with prejudice in February 2022, with the September 30, 2021 opinion vacated.
Case overview & background
Plain-language overview of the case: parties, accused product, patents at issue, and why the suit matters.
Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).
Key legal developments & outcome
Major rulings, motions, claim construction, settlements, and the present posture or final disposition.
Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).
Plaintiff representatives
Counsel of record for the plaintiff(s): attorneys, firms, and roles (lead counsel, of counsel, local counsel).
Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).
Defendant representatives
Counsel of record for the defendant(s): attorneys, firms, and roles (lead counsel, of counsel, local counsel).
Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).